[Sideeffects of colloids (author's transl)].
A prospective controlled trial during 1975 and 1976 has revealed that none of the colloids in clinical use (plasma protein solution, gelatine, hydroxyethylstarch and dextran) is free from the risk of anaphylactoid reactions. Even though the incidence of anaphylactoid reactions is low (0.03%), lethal outcome might be encountered. Between the colloids differences exist as far as manifestation (skin, circulatory and respiratory system) and degree of severity (I--IV) of anaphylactoid reactions are concerned. Since the underlying pathomechanisms have not been elucidated yet, true prophylactic measures are unknown. Therefore, it is mandatory to control the patient very carefully at the beginning of infusion; early symptoms of anaphylactoid reactions should trigger immediate therapeutic measures. Recent findings showed that the anaphylactoid reactions to dextran might be elicited by immune complexes. A new model was developed to investigate the chances of specific prophylactic procedures.
D000707:Anaphylaxis / Q000139:chemically induced; D001798:Blood Proteins / Q000009:adverse effects; D003102:Colloids; D003911:Dextrans / Q000009:adverse effects; D005780:Gelatin / Q000009:adverse effects; D006801:Humans; D006895:Hydroxyethyl Starch Derivatives / Q000009:adverse effects; D010952:Plasma Substitutes / Q000009:adverse effects*; D012996:Solutions
D001798:Blood Proteins; D003102:Colloids; D003911:Dextrans; D006895:Hydroxyethyl Starch Derivatives; D010952:Plasma Substitutes; D012996:Solutions; D005780:Gelatin
Nebenwirkungen bei der Anwendung kolloidaler Infusionslösungen.